Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: Egyesült ÁllamokFázis nélkül

Cleaner Long-tErm Assessment Registry - Venous Insights and Efficacy With eXtended Tracking

A legfontosabb adatok

Ki végzi
Argon Medical Devices
Hol
Edgewood, Fort Lauderdale, Indianapolis és Plano (Egyesült Államok)Mind a 4 helyszín megnézése
Azonosító
Állapot
Toboroz
Résztvevők
185 fő, tervezett
Kezdés
2026. febr. 4.
Várható befejezés
2029. jún.
A vizsgálat típusa
Megfigyeléses
A vizsgált kezelések
  • Aspiration thrombectomy system
A regiszteradat frissítve
2026. október 20.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults with a recent blood clot in a deep vein of the leg or pelvis. They will be treated first with the Cleaner Vac® Thrombectomy System, a device that sucks out the clot.

Életkor
18 years or older.
Nem
All sexes.
A betegség stádiuma
Deep vein thrombosis (DVT) in one or both legs. It must involve the femoral-popliteal, common femoral or iliac vein, or the inferior vena cava (IVC). Symptoms started within 6 weeks of enrollment. Imaging confirmed the clot within 14 days of the procedure.
Korábbi kezelés
The Cleaner Vac® device must be the first treatment for the clot. People cannot join if clot-dissolving drugs (thrombolytics) were used on the same vein in the previous 14 days.

A részvétel fő kizáró okai

  • Cannot take blood thinners, or cannot have iodine contrast dye even with medicine given beforehand.
  • Pregnancy.
  • Severe kidney problems (GFR < 30 ml/min) without dialysis. People already on dialysis can join.
  • Intermediate-high or high-risk clot in the lung (pulmonary embolism), or a known patent foramen ovale (PFO), a small opening between the heart's upper chambers.
  • Life expectancy less than 1 year due to advanced cancer, or long-term inability to walk.

A regiszter feltételei, szó szerint

Mind a 22 feltétel megnézéseKevesebb

Ki vehet részt

  • Participants must meet all the following criteria to be eligible for the study:
  • At least 18 years of age at the time of consent
  • Undergo frontline (primary) treatment with Cleaner Vac® Thrombectomy System in the peripheral venous vasculature and have at least one component introduced into the body
  • Written informed consent obtained through the IRB-approved ICF; For the DVT cohort, participants must meet all criteria above and below to be eligible for the study:
  • Present with unilateral or bilateral lower extremity DVT involving at least one of the following veins:; Femoral-popliteal vein; Common femoral vein; Iliac vein; Inferior Vena Cava (IVC)
  • DVT diagnosis confirmed by imaging within 14 days of the index procedure
  • Symptomatic DVT with onset within 6 weeks of enrollment

Ki nem vehet részt

  • Treatment of target venous segment with thrombolytics within previous 14 days of the index procedure
  • Current enrollment in another investigational device or drug study that may confound the results of this study. Studies requiring extended follow-up for products that were investigational but have since become commercially available are not considered investigational studies
  • Life expectancy less than 1 year due to advanced malignancy, as determined by the investigator at the time of enrollment
  • Known coagulation disorders both acquired (Heparin Induced Thrombocytopenia, etc.) or genetic (e.g., Factor V Leiden, etc.), thrombophilia, or hypercoagulable states that, in the opinion of the Investigator, cannot be medically managed throughout the study period
  • Known history of a Patent Foramen Ovale (PFO)
  • Patients with intermediate-high risk or high-risk pulmonary embolism (PE) defined as follows:; High-risk PE: Presence of hemodynamic instability, including cardiac arrest, obstructive shock (systolic blood pressure <90 mmHg or need for vasopressors with signs of end-organ hypoperfusion), or persistent hypotension (systolic BP <90 mmHg or a drop ≥40 mmHg for >15 minutes not due to other causes); Intermediate-high-risk PE: Hemodynamically stable patients with both right ventricular (RV) dysfunction (on echocardiography or CT) and elevated cardiac biomarkers (e.g., troponin)
  • Hemoglobin < 8.0 g/dL, INR > 2.0 before warfarin was started, or platelets < 50,000/µl which cannot be corrected prior to enrollment
  • Severe renal impairment (estimated GFR < 30 ml/min) in patients who are not yet on dialysis. Patients with GFR <30 ml/min who are already on dialysis can be enrolled
  • Subjects will be excluded from the study if any of the following criteria are met:
  • Contraindication to systemic or therapeutic doses of anticoagulants
  • Contraindication to iodinated contrast that cannot be adequately premedicated
  • Patients that are pregnant
  • Known congenital anatomic anomalies of the inferior vena cava (IVC) or iliac veins
  • Complete infrarenal IVC occlusion
  • Chronic non-ambulatory status

Helyszínek itt: Egyesült Államok

  • St. Elizabeth Healthcare - EdgewoodEdgewood, Egyesült ÁllamokContact: Alisha HartmannRésztvevőt keres
  • Janna, LLCFort Lauderdale, Egyesült ÁllamokContact: Vicky RodriguezRésztvevőt keres
  • Indiana University HealthIndianapolis, Egyesült ÁllamokContact: Siji MathachanRésztvevőt keres
  • Baylor Scott & White The Heart Hospital - PlanoPlano, Egyesült ÁllamokContact: Erika V Ortiz, BARésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

The primary objective of this clinical investigation is to evaluate the safety and effectiveness of the Cleaner Vac® Thrombectomy System for the treatment of thrombus in patients with lower extremity proximal deep vein thrombosis (DVT). This prospective, multi-center, open-label study will assess clinical outcomes, device performance, and procedural success in a single DVT study cohort.

A vizsgálat csoportja

  • DVT Subgroup

    This is a defined cohort focused on patients with lower extremity proximal deep vein thrombosis (DVT) who will undergo treatment with Cleaner Vac® Thrombectomy System. Participants will complete required follow-up at discharge and at 1, 6, 12, and 24 months.

    Kezelés: Aspiration thrombectomy system

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Prospective, Multi-Center, Open-Label Clinical Investigation of the Cleaner Vac® Thrombectomy System for Treatment of Lower Extremity Proximal Deep Vein Thrombosis (DVT)
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 15.
A regiszteradat frissítve
2026. október 20.